**INSTRUCTIONS:** Please complete this form in its entirety. **Providing only a reference publication will not be accepted.**

6th April 2015

**Date:**

Findlay

**Laboratory Name:**

Greg Findlay

**Your Name:**

**Is testing ongoing such that you are waiting for future bleeds?:** [ ]  Yes [ ]  No

Usp38(N)

**Antibody Name:**

Usp38(1-231)

**Full Antigen Name:**

**Full Antigen Sequence** *(please include full amino acid sequence)*:

MDKILEGLVSSSHPLPLKRMIVRKVVEFAEHWLDEAQCEAMFDLTTRLILEGQDPFQRQVGHQVLEAYARYHRPEFESFFNKTFVLGLLQQGYHSVDRKDVAILDYIHNGLKLIMSCPSVLDLFSLLQVEVLRMVCERPEPVLCARLSDLLTDFVQCVPKGKLSVTFCQQLVRTIGHFQCVSTQEKELREYVSQVTKVSTLLQNIWKAEPSTLLPSLQEVFASISSTDASF

**Antigen Species** *(Please indicate whether the antigen corresponds to the human/mouse/rat or other species)*:

Mouse

**Bleeds Tested In this Report** *(Please check ALL those that apply)***:**

[ ]  1 [ ]  2 [ ]  3 [ ]  4 [ ]  5 [ ]  6 [ ]  7

**SUCCESSFUL APPLICATIONS:**

Instructions: Please check each box below and indicate clearly all the applications that each bleed was tested in and if it was successful

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Immunoblot** | **Immunoprecipitation** | **Immunofluorescence** |
|  | **Tested** | **Successful** | **Tested** | **Successful** | **Tested** | **Successful** |
| **Bleed #1** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #2** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #3** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #4** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #5** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #6** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |
| **Bleed #7** | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  | [ ]  |

**BEST Working Bleed:**

**PUBLICATIONS:** *Please identify all publications to-date that include data supporting the successful use of the antibody*

1. Name, et al, Year, Title, Journal
	* PMID *(mandatory)*
2. Name, et al. (*submitted*)

Antibody was tested by immunoblotting total cell extracts from mouse Embryonic Stem Cells wherein CRISPR genome editing was used to disrupt either an irrelevant gene (Control, left) or the gene encoding antibody target protein (Right). The specific band corresponding to the correct molecular weight for the antigenic target is indicated with an arrow. A total Erk1/2 immunoblot is included as a loading control.

****